Cambridge-founded automated cell analytics platform Sphere Fluidics has added $2m of funding, bringing its lifetime haul to $14.9m.

Facit-backed oncological development initiative Triphase Accelerator has struck a deal with Celgene for its TRPH-395 blood cancer treatment as the drug nears clinical trials

Leaps by Bayer, 6 Dimensions Capital and Alexandria Venture Investments are among the investors that have provided series A funding for the biomolecular medicine startup.

Partners Healthcare has resubscribed in the round, which included fellow corporates Gilead Sciences and Orient Life, increasing the long-lasting medicine developer's total funding to $78m.

Having emerged from the Merck Serono Entrepreneur Partnership Program (EPP) in 2015, Prexton Therapeutics raised a total $41m of funding before it was acquired by pharmaceutical firm Lundbeck for an estimated $1.1bn last year.

Shepherd Kaplan Krochuck and Molex Ventures have helped the epinephrine pen developer raise $12.1m of a funding round expected to close at $39m.

Greenoaks Capital has led a $500m funding round for Clover Health, a health insurance provider that last raised cash in a $130m GV-backed round in 2017.

US-based pension fund Lacera has provided $100m for the latest fund to be raised by corporate venturing unit Lilly Asia Ventures, which has a $750m target.

Existing backer SoftBank China was among the participants in a series E round that will support the expansion of Taimei Technology's clinical trial management platform.

Hana Ventures intends to provide some $890m in loans and direct investment for VC firms targeting biotech and ICT companies, over the next three years.